Long-term efficacy and safety of sustained-release diltiazem in the treatment of hypertension

The long-term efficacy and safety of sustained-release diltiazem (Tilazem; Parke-Davis) were evaluated. A total of 27 young, physically active patients with hypertension were followed up for 17 months. On a dosage of 90 mg twice daily, adequate blood pressure reduction was obtained in 23 patients (85%). No adverse effects were noted